drugset
drugset / Trial / NCT05552274

FTIH of ECC4703 in Healthy Volunteers

NCT05552274 ↗

Phase 0 Completed 75 enrolled Eccogene
RandomizedParallel-groupTriple-blindTreatment

Summary

This is a Phase 1, randomized, double-blind, placebo-controlled, single ascending dose and multiple ascending dose study of ECC4703 in healthy volunteers and participants with treatment unnecessary LDL-C under 160 mg/dL

Timeline

Start
2022-08-16
Primary completion
2023-10-26
Completion
2023-10-26

Drugs

EvaluationDrugModalityDoseRoute
Subject ECC4703 Unknown 1 mg Oral
Subject ECC4703 Unknown 4 mg Oral
Subject ECC4703 Unknown 12 mg Oral
Subject ECC4703 Unknown 32 mg Oral
Subject ECC4703 Unknown 40 mg Oral
Subject ECC4703 Unknown 80 mg Oral
Subject ECC4703 Unknown 160 mg Oral
Subject ECC4703 Unknown 320 mg Oral
Subject ECC4703 Unknown 400 mg Oral

Indications

metabolic dysfunction-associated steatohepatitis